Home > Insider Trading > Filing (0001181431-12-041387)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1382911	Orexigen Therapeutics Inc.	OREX	Pharmaceutical Preparations (2834)	651178822

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1403571	D Heather Turner	C/O Orexigen Therapeutics, Inc. 3344 N. Torrey Pines Court, Suite 200 La Jolla CA 92037	Svp, Gen. Counsel & Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-07-17	82,433	$1.66	82,433	No	4	M	Direct
Common Stock	Disposition	2012-07-17	82,433	$7.68	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2012-07-17	82,433	$0.00	82,433	$1.66

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,010,963		2021-07-24	No	4	M	Direct

Footnotes

The exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2012.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2012.
The sale price set forth in Column 4 of this line represents the weighted average sale price of the shares sold ranging from $7.66 to $7.72 per share. Upon request by the Commission staff, the Company, or a security holder of the Company, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
1/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) (which option is referred to in this Form 4 as the "Replacement Grant") shall vest on the same day of each one-month period of the reporting person's service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
Not applicable.